Michael C Heinrich

32PUBLICATIONS
144CO-AUTHORS
Haematological tumoursEvolutionary ecologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPrimary health care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Jul 16, 2026
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.

|Jun 11, 2026
Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom

|Apr 09, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.

Jorge E Cortes, Fabian Lang, Delphine Rea

|Apr 09, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.

Andreas Hochhaus, Dong-Wook Kim, Jorge E Cortes

|Sep 25, 2024
A Novel Human SDHA-Knockout Cell Line Model for the Functional Analysis of Clinically Relevant SDHA Variants.

Jason D Kent, Lillian R Klug, Michael C Heinrich

Pageof 6

Frequent Collaborators

11 joint publications

Sebastian Bauer

8 joint publications

Robin L Jones

7 joint publications

Margaret von Mehren

7 joint publications

Suzanne George